VASCULAR BIOGENICS LTD (VBLT) Stock News
NASDAQ:VBLT - Nasdaq - IL0011327454 - Common Stock - Currency: USD
VBLT Latest News, Press Relases and Analysis
VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting
Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq...
Why Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Gainers SuperCom Ltd. (NASDAQ: SPCB) shares rose 78.4% to $0.6425 in pre-market trading, after falling 13% on Monday.
Why Avidity Biosciences Shares Are Trading Higher By Around 9%: 20 Stocks Moving Premarket
Gainers Maris-Tech Ltd. (NASDAQ: MTEK) shares rose 38% to $1.38 in pre-market trading, after gaining 6% on Friday. Maris-Tech, on Friday, disclosed the launch of Jupiter Drones, an innovative, drone-oriented solution based on Maris-Tech's Jupiter Nano platform.
VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting
Shareholders of record as of September 5, 2023 are eligible to vote at the VBL Shareholder Meeting on October 12, 2023...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of the biggest pre-market stock movers that traders will want to watch on Thursday!
VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC
Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI’IN,...
VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Merger with Notable expected to close in late September or October, subject to VBL’s S-4 registration statement being declared effective and shareholder...
VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Recently filed S-4 registration statement for proposed merger with Notable; expects to close the transaction in Q3 2023, subject to SEC review and...
VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
MODIIN, Israel and NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), today announced financial results for the fiscal...
Vascular Biogenics stock dips amid sale of manufacturing facility to Aleph Farms
Aleph Farms said it has acquired a manufacturing facility in Modi'in, Israel, and certain related assets from VBL Therapeutics (VBLT).Last week, Israel-based Vascular Biogenics...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start off trading on Friday with a breakdown of the biggest pre-market stock movers worth keeping an eye on!
Why Are Chip Stocks Up Today?
Chip stocks are on the rise Thursday and we've got all the details investors need to know about the sector's gains today!
Why Is Vascular Biogenics (VBLT) Stock Up 52%?
Vascular Biogenics (VBLT) stock is rocketing higher on Thursday following news of a merger with Notable Labs and a ticker change.
VBLT stock rises on all-stock merger deal with Notable Labs (NASDAQ:VBLT)
Israeli biotech Vascular Biogenics (VBLT), known as VBL Therapeutics, added ~85% after the company and U.S.-based Notable Labs announced an all-stock merger deal. Read the full story here.
VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement
Merger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through...
VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
MODIIN, Israel and NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for...
VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Continued progress on previously announced strategic process to maximize shareholder value...